IL190544A - Quaternary history of alpha-aminocarboxamide as modulators of voltage-activated calcium channels - Google Patents
Quaternary history of alpha-aminocarboxamide as modulators of voltage-activated calcium channelsInfo
- Publication number
- IL190544A IL190544A IL190544A IL19054408A IL190544A IL 190544 A IL190544 A IL 190544A IL 190544 A IL190544 A IL 190544A IL 19054408 A IL19054408 A IL 19054408A IL 190544 A IL190544 A IL 190544A
- Authority
- IL
- Israel
- Prior art keywords
- modulators
- voltage
- sodium channels
- gated sodium
- quaternary alpha
- Prior art date
Links
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 title 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520578A GB0520578D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0523030A GB0523030D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603897A GB0603897D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0609159A GB0609159D0 (en) | 2006-05-09 | 2006-05-09 | Novel Compounds |
| GB0618511A GB0618511D0 (en) | 2006-09-20 | 2006-09-20 | Novel compounds |
| PCT/EP2006/009732 WO2007042240A1 (en) | 2005-10-10 | 2006-10-06 | Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL190544A0 IL190544A0 (en) | 2008-11-03 |
| IL190544A true IL190544A (en) | 2013-06-27 |
Family
ID=37762326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL190544A IL190544A (en) | 2005-10-10 | 2008-03-31 | Quaternary history of alpha-aminocarboxamide as modulators of voltage-activated calcium channels |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7803833B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1934176B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5139306B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080059297A (cg-RX-API-DMAC7.html) |
| AR (1) | AR057869A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE543797T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006301471A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0617189A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2625763A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR9926A (cg-RX-API-DMAC7.html) |
| EA (1) | EA200801068A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2381686T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL190544A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20082122L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ567030A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20070495A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200728258A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007042240A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| WO2007042250A1 (en) * | 2005-10-10 | 2007-04-19 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| ES2536694T3 (es) | 2009-09-14 | 2015-05-27 | Convergence Pharmaceuticals Limited | Procedimiento para preparar derivados de alfa-carboxamida |
| JP2011232320A (ja) * | 2009-10-01 | 2011-11-17 | Sony Corp | 生体内物質検出用プローブ、および該生体内物質検出用プローブを用いた生体内物質検出装置 |
| ES2786298T3 (es) | 2011-03-03 | 2020-10-09 | Zalicus Pharmaceuticals Ltd | Inhibidores de benzimidazol del canal de sodio |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| GB201209670D0 (en) * | 2012-05-31 | 2012-07-18 | Convergence Pharmaceuticals | Novel compounds |
| US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| WO2016160574A2 (en) * | 2015-03-27 | 2016-10-06 | Scifluor Life Sciences, Inc. | Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds |
| MX2020003811A (es) | 2017-10-05 | 2021-01-15 | Biogen Inc | Proceso para preparar derivados de alfa-carboxamida pirrolidina. |
| WO2019075073A2 (en) | 2017-10-10 | 2019-04-18 | Biogen Inc. | PROCESS FOR THE PREPARATION OF SPIRO DERIVATIVES |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| YU68701A (sh) | 1999-03-26 | 2004-09-03 | Euro-Celtique S.A. | Aril supstituisani pirazoli, imidazoli, oksazoli, tiazoli i piroli i njihova upotreba |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| PA8583001A1 (es) * | 2002-09-20 | 2004-04-23 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US7589116B2 (en) | 2003-04-03 | 2009-09-15 | Merck & Co. Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| AU2004232936B2 (en) | 2003-04-18 | 2008-10-30 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US20060217365A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating mood disorders |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| EP1877381A1 (en) | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| WO2006119451A1 (en) | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| JP2008540665A (ja) | 2005-05-19 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なビアリール |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| CA2676357A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136996A patent/TW200728258A/zh unknown
- 2006-10-06 EA EA200801068A patent/EA200801068A1/ru unknown
- 2006-10-06 US US11/570,564 patent/US7803833B2/en active Active
- 2006-10-06 AU AU2006301471A patent/AU2006301471A1/en not_active Abandoned
- 2006-10-06 PE PE2006001224A patent/PE20070495A1/es not_active Application Discontinuation
- 2006-10-06 BR BRPI0617189-3A patent/BRPI0617189A2/pt not_active IP Right Cessation
- 2006-10-06 JP JP2008534911A patent/JP5139306B2/ja not_active Expired - Fee Related
- 2006-10-06 NZ NZ567030A patent/NZ567030A/en unknown
- 2006-10-06 WO PCT/EP2006/009732 patent/WO2007042240A1/en not_active Ceased
- 2006-10-06 ES ES06806111T patent/ES2381686T3/es active Active
- 2006-10-06 EP EP06806111A patent/EP1934176B1/en active Active
- 2006-10-06 KR KR1020087011273A patent/KR20080059297A/ko not_active Withdrawn
- 2006-10-06 AT AT06806111T patent/ATE543797T1/de active
- 2006-10-06 CA CA002625763A patent/CA2625763A1/en not_active Abandoned
- 2006-10-09 AR ARP060104440A patent/AR057869A1/es active IP Right Grant
-
2008
- 2008-03-31 IL IL190544A patent/IL190544A/en active IP Right Grant
- 2008-04-25 CR CR9926A patent/CR9926A/es not_active Application Discontinuation
- 2008-05-06 NO NO20082122A patent/NO20082122L/no not_active Application Discontinuation
-
2010
- 2010-08-04 US US12/850,330 patent/US8153623B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100324022A1 (en) | 2010-12-23 |
| US8153623B2 (en) | 2012-04-10 |
| EP1934176A1 (en) | 2008-06-25 |
| NZ567030A (en) | 2011-03-31 |
| CR9926A (es) | 2008-07-29 |
| CA2625763A1 (en) | 2007-04-19 |
| ATE543797T1 (de) | 2012-02-15 |
| US7803833B2 (en) | 2010-09-28 |
| EP1934176B1 (en) | 2012-02-01 |
| KR20080059297A (ko) | 2008-06-26 |
| TW200728258A (en) | 2007-08-01 |
| NO20082122L (no) | 2008-07-02 |
| AU2006301471A1 (en) | 2007-04-19 |
| WO2007042240A1 (en) | 2007-04-19 |
| AR057869A1 (es) | 2007-12-26 |
| US20080293753A1 (en) | 2008-11-27 |
| BRPI0617189A2 (pt) | 2011-07-19 |
| ES2381686T3 (es) | 2012-05-30 |
| JP2009514801A (ja) | 2009-04-09 |
| JP5139306B2 (ja) | 2013-02-06 |
| IL190544A0 (en) | 2008-11-03 |
| EA200801068A1 (ru) | 2009-02-27 |
| PE20070495A1 (es) | 2007-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190544A0 (en) | Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels | |
| ZA200805338B (en) | Heterocyclic derivatives as modulators of ion channels | |
| EP1922068A4 (en) | INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS | |
| AP2516A (en) | 2-Pyridine carboxamide derivatives as sodium channel modulators | |
| IL192627A0 (en) | Prolinamide derivatives as sodium channel modulators | |
| ZA200709961B (en) | Bicyclic derivatives as modulators of ion channels | |
| ZA200800191B (en) | Indane derivatives as modulators of ion channels | |
| IL174419A0 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
| ZA200800698B (en) | Pyrazole derivatives as therapeutic agents | |
| IL188388A0 (en) | Pyrazole derivatives as cb1 modulators | |
| ZA200901055B (en) | Oxazolidone derivatives as PR modulators | |
| ZA200609234B (en) | Substituted azeplne derivatives as serotonin receptor modulators | |
| ZA200802877B (en) | Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels | |
| IL177729A0 (en) | N-piperidine derivatives as ccr3 modulators | |
| GB0704737D0 (en) | Eyeglass frame | |
| ZA200802879B (en) | Prolinamide derivatives as sodium channel modulators | |
| EP1928827A4 (en) | PYRROLE DERIVATIVES AS THERAPEUTIC AGENTS | |
| HK1119693A (en) | Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels | |
| IL186143A0 (en) | Pro-drugs of n-thiazol-2yl-benzamide derivatives | |
| ZA200510385B (en) | Propionamide derivatives useful as androgen receptor modulators | |
| ZA200707966B (en) | Pro-drugs of n-thiazol-2yl-benzamide derivatives | |
| TWM298716U (en) | Improved structure of glasses without frame | |
| ZA200607353B (en) | N-Piperidine derivatives as CCR3 modulators | |
| PL381715A1 (pl) | Nowe pochodne piperazynowe dialkilooksindoli | |
| HUP0500461A3 (en) | Pyperazine derivatives of alkyl-oxindoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |